miTr Nx Mx cohort (n=226)	COMPLETELY covered by CTV (n=107)	NOT covered by CTV (n=28)	PARTIALLY covered by CTV (n=91)	p-value
Median Age*, yr (IQR)	69 (63 - 73)	69 (67 – 76.3)	70 (63.25 - 75)	0.38^{a}
Serum PSA ng/ml*, Median (IQR)	1.40 (0.6 - 2.4)	0. 92 (0.59 – 1.76)	1.3 (0.57 – 4.25)	0.27^{a}
Tumor volume (ml), Median (IQR)	0.7 (0.37 – 1.33)	0.7 (0.37 – 1.31)	1.09 (0.51 – 2.83)	0.03^{a}
NCCN risk group, n (%)** o Low-risk o Intermediate risk o High risk o Very high o Not available	 8 (9) 35 (41) 23 (27) 19 (22) 21 	 1 (4) 14 (54) 7 (27) 4 (15) 2 	 0 32 (43) 22 (30) 20 (27) 17 	n/a
Surgical margin involvement, n (%)** o No o Yes o Not available	 42 (59) 29 (41) 36 	19 (79)5 (21)4	38 (62)23 (38)31	0.15 ^b
Location of recurrence partially or completely exceeding the CTV, n (%) O Posterior O Postero-lateral O Postero-inferior O Anterior O Superior O Inferior O Laterally	n/a	 10 (36) 7 (25) 4 (14) 0 0 0 0 7 (25) 0 	 47 (52) 27 (30) 4 (4) 1 (1) 4 (4) 5 (5) 2 (2) 	n/a
Local organs involvement, n (%) O Rectal wall involvement O Bladder wall involvement	o 1 (1) o 8 (8)	o 9 (32) o 0	o 9 (10) o 2 (2)	0.001°

Supplementary Table 1. Clinical characteristics and location of recurrences based on the three outcomes in the whole cohort (miTr Nx Mx). Age and PSA are at time of PET. The percentage was calculated on the total number of patients with the data available in the selected category. ^a One-way ANOVA; ^b Spearman ρ correlation matrix; ^c chi-square test.